601 related articles for article (PubMed ID: 11331613)
21. Role of VHL gene mutation in human cancer.
Kim WY; Kaelin WG
J Clin Oncol; 2004 Dec; 22(24):4991-5004. PubMed ID: 15611513
[TBL] [Abstract][Full Text] [Related]
22. Von Hippel-Lindau tumor suppressor protein and hypoxia-inducible factor in kidney cancer.
Maynard MA; Ohh M
Am J Nephrol; 2004; 24(1):1-13. PubMed ID: 14654728
[TBL] [Abstract][Full Text] [Related]
23. The von Hippel-Lindau tumor suppressor, hypoxia-inducible factor-1 (HIF-1) degradation, and cancer pathogenesis.
Pugh CW; Ratcliffe PJ
Semin Cancer Biol; 2003 Feb; 13(1):83-9. PubMed ID: 12507560
[TBL] [Abstract][Full Text] [Related]
24. Mechanism of regulation of the hypoxia-inducible factor-1 alpha by the von Hippel-Lindau tumor suppressor protein.
Tanimoto K; Makino Y; Pereira T; Poellinger L
EMBO J; 2000 Aug; 19(16):4298-309. PubMed ID: 10944113
[TBL] [Abstract][Full Text] [Related]
25. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas.
Wiesener MS; Münchenhagen PM; Berger I; Morgan NV; Roigas J; Schwiertz A; Jürgensen JS; Gruber G; Maxwell PH; Löning SA; Frei U; Maher ER; Gröne HJ; Eckardt KU
Cancer Res; 2001 Jul; 61(13):5215-22. PubMed ID: 11431362
[TBL] [Abstract][Full Text] [Related]
26. Inactivation of VHL by tumorigenic mutations that disrupt dynamic coupling of the pVHL.hypoxia-inducible transcription factor-1alpha complex.
Miller F; Kentsis A; Osman R; Pan ZQ
J Biol Chem; 2005 Mar; 280(9):7985-96. PubMed ID: 15611064
[TBL] [Abstract][Full Text] [Related]
27. Nur77 activated by hypoxia-inducible factor-1alpha overproduces proopiomelanocortin in von Hippel-Lindau-mutated renal cell carcinoma.
Choi JW; Park SC; Kang GH; Liu JO; Youn HD
Cancer Res; 2004 Jan; 64(1):35-9. PubMed ID: 14729605
[TBL] [Abstract][Full Text] [Related]
28. Ubiquitination of hypoxia-inducible factor requires direct binding to the beta-domain of the von Hippel-Lindau protein.
Ohh M; Park CW; Ivan M; Hoffman MA; Kim TY; Huang LE; Pavletich N; Chau V; Kaelin WG
Nat Cell Biol; 2000 Jul; 2(7):423-7. PubMed ID: 10878807
[TBL] [Abstract][Full Text] [Related]
29. Expression of HIF-1 and ubiquitin in conventional renal cell carcinoma: relationship to mutations of the von Hippel-Lindau tumor suppressor gene.
Hughson MD; He Z; Liu S; Coleman J; Shingleton WB
Cancer Genet Cytogenet; 2003 Jun; 143(2):145-53. PubMed ID: 12781449
[TBL] [Abstract][Full Text] [Related]
30. Renal cell carcinoma risk in type 2 von Hippel-Lindau disease correlates with defects in pVHL stability and HIF-1alpha interactions.
Knauth K; Bex C; Jemth P; Buchberger A
Oncogene; 2006 Jan; 25(3):370-7. PubMed ID: 16261165
[TBL] [Abstract][Full Text] [Related]
31. Loss of pVHL is sufficient to cause HIF dysregulation in primary cells but does not promote tumor growth.
Mack FA; Rathmell WK; Arsham AM; Gnarra J; Keith B; Simon MC
Cancer Cell; 2003 Jan; 3(1):75-88. PubMed ID: 12559177
[TBL] [Abstract][Full Text] [Related]
32. The von Hippel-Lindau protein interacts with heteronuclear ribonucleoprotein a2 and regulates its expression.
Pioli PA; Rigby WF
J Biol Chem; 2001 Oct; 276(43):40346-52. PubMed ID: 11517223
[TBL] [Abstract][Full Text] [Related]
33. VHL type 2B mutations retain VBC complex form and function.
Hacker KE; Lee CM; Rathmell WK
PLoS One; 2008; 3(11):e3801. PubMed ID: 19030229
[TBL] [Abstract][Full Text] [Related]
34. Genotype-phenotype correlations in VHL exon deletions.
McNeill A; Rattenberry E; Barber R; Killick P; MacDonald F; Maher ER
Am J Med Genet A; 2009 Oct; 149A(10):2147-51. PubMed ID: 19764026
[TBL] [Abstract][Full Text] [Related]
35. The von Hippel-Lindau tumor suppressor gene and kidney cancer.
Kaelin WG
Clin Cancer Res; 2004 Sep; 10(18 Pt 2):6290S-5S. PubMed ID: 15448019
[TBL] [Abstract][Full Text] [Related]
36. Inactivation of the von Hippel-Lindau (VHL) tumour suppressor gene and allelic losses at chromosome arm 3p in primary renal cell carcinoma: evidence for a VHL-independent pathway in clear cell renal tumourigenesis.
Clifford SC; Prowse AH; Affara NA; Buys CH; Maher ER
Genes Chromosomes Cancer; 1998 Jul; 22(3):200-9. PubMed ID: 9624531
[TBL] [Abstract][Full Text] [Related]
37. The von Hippel-Lindau tumor suppressor protein: roles in cancer and oxygen sensing.
Kaelin WG
Cold Spring Harb Symp Quant Biol; 2005; 70():159-66. PubMed ID: 16869749
[TBL] [Abstract][Full Text] [Related]
38. Expression of hypoxia-inducible factors in human renal cancer: relationship to angiogenesis and to the von Hippel-Lindau gene mutation.
Turner KJ; Moore JW; Jones A; Taylor CF; Cuthbert-Heavens D; Han C; Leek RD; Gatter KC; Maxwell PH; Ratcliffe PJ; Cranston D; Harris AL
Cancer Res; 2002 May; 62(10):2957-61. PubMed ID: 12019178
[TBL] [Abstract][Full Text] [Related]
39. The HIF and other quandaries in VHL disease.
Tarade D; Ohh M
Oncogene; 2018 Jan; 37(2):139-147. PubMed ID: 28925400
[TBL] [Abstract][Full Text] [Related]
40. Selection of mutant CHO cells with constitutive activation of the HIF system and inactivation of the von Hippel-Lindau tumor suppressor.
Vaux EC; Wood SM; Cockman ME; Nicholls LG; Yeates KM; Pugh CW; Maxwell PH; Ratcliffe PJ
J Biol Chem; 2001 Nov; 276(47):44323-30. PubMed ID: 11555645
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
